구조생물학 및 분자 모델링 기술 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the structural biology and Molecular Modeling Techniques market size is expected to grow from USD 10.31 billion in 2025 to USD 11.9 billion in 2026 and is forecast to reach USD 24.3 billion by 2031 at 15.38% CAGR over 2026-2031.

This report is Segmented by Tool (SaaS & Stand-Alone Platforms, Visualization & Analysis Suites, Other Tools), Application (Drug Discovery, Drug Development, Protein Engineering, Other Applications), End-User (Pharmaceutical & Biotech Companies, Cros, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Structural Biology And Molecular Modeling Techniques Market Trends and Insights

Rapid Adoption of AI-Driven Drug-Discovery Platforms

Eli Lilly's USD 1 billion commitment to a quantum chemistry start-up exemplifies how top pharma dedicates full discovery pipelines to machine-learning ensembles. Widespread deployment of AlphaFold 3, Boltz-2, and similar tools drives parallel explorations of conformational landscapes that once took years. FDA credibility frameworks now accept virtual screens as decision-quality evidence, lowering preclinical attrition by 30-40%. Vendors integrate molecular dynamics, docking, and graph neural networks within unified workspaces so that chemists iterate designs in real time. Competitive advantage increasingly hinges on orchestrating outputs from multiple AI models rather than depending on a single proprietary engine.

Rising Prevalence of Chronic Diseases

Neurodegeneration, oncology, and metabolic disorders require poly-pharmacology approaches that only structure-enabled modeling can support. FDA oncology dosage guidance released in 2024 underlines the need for predictive exposure-response simulations before first-in-human trials. Multi-target algorithms optimize binding affinities across interconnected pathways while monitoring off-target risks. Demand rises for platforms that trace allosteric shifts and protein-protein interactions through entire cellular contexts. As chronic disease complexity grows, simulation depth-not just speed-becomes critical, fueling further uptake of high-precision hybrid quantum-mechanical methods.

High Cost of Sophisticated Instrumentation

Advanced cryo-electron microscopy systems and high-performance computing clusters require capital investments exceeding USD 10 million, creating significant barriers for smaller research organizations and emerging market institutions. The operational costs extend beyond initial equipment purchases to include specialized facility requirements, maintenance contracts, and continuous software licensing fees that can consume 40-50% of annual research budgets. Cloud-based alternatives partially address these challenges, but data transfer costs and latency issues limit their effectiveness for real-time collaborative research. The concentration of sophisticated instrumentation in well-funded institutions creates research inequality, where breakthrough discoveries increasingly emerge from a small number of elite organizations with access to cutting-edge technology. This dynamic potentially slows overall market growth by limiting the diversity of research approaches and reducing the number of active participants in drug discovery innovation.

Other drivers and restraints analyzed in the detailed report include:

1. Advances in Cryo-EM & High-Resolution Imaging
2. Growth in Cloud-Native Collaborative Research Environments
3. Shortage of Cross-Disciplinary Skilled Personnel

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

SaaS and stand-alone platforms captured 41.02% value in 2025, underscoring subscription economics that ease capital barriers for newcomers. Within this bracket, high-throughput molecular dynamics engines lead daily usage metrics, while quantum-mechanical solvers find traction in select programs demanding sub-kcal/mol accuracy. Visualization suites outpace all other tool types with a 16.24% CAGR, propelled by intuitive GUIs that let medicinal chemists, structural biologists, and data scientists co-explore conformational ensembles without coding experience. Open-source entrants such as VTX and OpenMMDL broaden access and chip away at proprietary market dominance. The structural biology and molecular modeling techniques market size for visualization suites is projected to expand steadily as GPU rendering costs decline and cloud delivery normalizes.

Vendor strategies coalesce around integrated ecosystems that knit together docking, free-energy calculations, and AI-guided property prediction under unified authentication and billing. Acquisitions concentrate niche algorithms into larger stacks, creating switching costs that discourage fragmentation. The structural biology and molecular modeling techniques market repeatedly rewards platforms that minimize data handoffs, and this mindset continues to drive consolidation waves through 2030.

Complete Report Scope:

• By Tool
  • Software-as-a-Service (SaaS) & Stand-alone Platforms
    • Homology Modeling
    • Threading / Fold Recognition
    • Molecular Dynamics Simulation
    • Quantum-mechanical / Hybrid Methods
  • Visualization & Analysis Suites
  • Other Tools
• By Application
  • Drug Discovery
  • Drug Development / Lead Optimization
  • Protein Engineering & Synthetic Biology
  • Other Applications
• By End-User
  • Pharmaceutical & Biotech Companies
  • Contract Research Organizations
  • Academic & Government Institutes
  • Software Vendors & Platform Providers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.41% of global revenue in 2025, buoyed by NIH budget upticks and a regulatory culture that explicitly embraces AI-generated evidence. High-density clusters in Boston, San Diego, and Toronto provide fertile ground for start-ups, yet escalating cloud costs and wage inflation test sustainability margins for seed-stage ventures. The region's academic-industry symbiosis remains a powerful growth engine, particularly for pre-competitive tool development grants that later mature into commercial differentiators. Federal agencies streamline review pathways, trimming submission cycles and accelerating commercial payback for successful assets.

Europe preserves steady momentum through coordinated public-private initiatives and the September 2024 EMA reflection paper that harmonizes AI governance across member states. Data-sovereignty directives complicate multi-regional data lakes, but domestically hosted clouds mitigate compliance gaps. The structural biology and molecular modeling techniques market size for European consortia rises as cross-border Horizon projects subsidize large-scale cryo-EM networks and quantum research corridors. Asia-Pacific commands the fastest growth trajectory at 16.21% CAGR. Chinese quantum computing labs funnel state incentives toward drug-discovery algorithms capable of teasing apart exponentially large Hilbert spaces. Japan's leadership in cryo-EM infrastructure complements its world-class supercomputers, producing high-fidelity structure sets that feed regional AI efforts. India scales cloud-first biotech incubators, translating its software engineering prowess into cost-effective simulation services. South Korea and Australia focus on niche strengths-biosensors and translational genomics respectively-integrating outputs into the wider regional ecosystem. Collectively these initiatives reshape competitive parity in the structural biology and molecular modeling techniques market. The Middle East, Africa, and South America record nascent yet promising adoption curves. Government technology free zones in the Gulf invite Western software partners through tax incentives, while Brazil leverages public university networks to perform agro-biodiversity modeling. Although absolute spend remains modest, collaborative frameworks lay groundwork for long-term participation in the structural biology and molecular modeling techniques industry.

1. Schrodinger Inc.
2. Dassault Systemes (BIOVIA)
3. Thermo Fisher Scientific
4. Agilent Technologies
5. Illumina
6. Bruker
7. Chemical Computing Group
8. PerkinElmer Informatics
9. Certara
10. OpenEye Scientific
11. Acellera
12. Biomax Informatics
13. Charles River
14. HORIBA
15. CD BioSciences
16. Agile Molecule
17. BioSolveIT
18. Simulations Plus
19. Genedata
20. Q-Chem Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapid Adoption of AI-Driven Drug-Discovery Platforms
  • 4.2.2 Rising Prevalence of Chronic Diseases
  • 4.2.3 Advances in Cryo-EM & High-Resolution Imaging
  • 4.2.4 Growth in Cloud-Native Collaborative Research Environments
  • 4.2.5 Increasing Use of Digital-Twin Proteins for In-Silico Toxicity Screening
  • 4.2.6 Open-Access Structural Databases Enabling Decentralized Innovation
• 4.3 Market Restraints
  • 4.3.1 High Cost of Sophisticated Instrumentation
  • 4.3.2 Shortage of Cross-Disciplinary Skilled Personnel
  • 4.3.3 Data-Sovereignty Limits on Cross-Border Collaboration
  • 4.3.4 Algorithmic Bias in AI-Based Molecular Modeling
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Intensity of Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Tool
  • 5.1.1 Software-as-a-Service (SaaS) & Stand-alone Platforms
    • 5.1.1.1 Homology Modeling
    • 5.1.1.2 Threading / Fold Recognition
    • 5.1.1.3 Molecular Dynamics Simulation
    • 5.1.1.4 Quantum-mechanical / Hybrid Methods
  • 5.1.2 Visualization & Analysis Suites
  • 5.1.3 Other Tools
• 5.2 By Application
  • 5.2.1 Drug Discovery
  • 5.2.2 Drug Development / Lead Optimization
  • 5.2.3 Protein Engineering & Synthetic Biology
  • 5.2.4 Other Applications
• 5.3 By End-User
  • 5.3.1 Pharmaceutical & Biotech Companies
  • 5.3.2 Contract Research Organizations
  • 5.3.3 Academic & Government Institutes
  • 5.3.4 Software Vendors & Platform Providers
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Schrodinger Inc.
  • 6.3.2 Dassault Systemes (BIOVIA)
  • 6.3.3 Thermo Fisher Scientific Inc.
  • 6.3.4 Agilent Technologies, Inc.
  • 6.3.5 Illumina Inc.
  • 6.3.6 Bruker Corporation
  • 6.3.7 Chemical Computing Group
  • 6.3.8 PerkinElmer Informatics
  • 6.3.9 Certara
  • 6.3.10 OpenEye Scientific
  • 6.3.11 Acellera Ltd.
  • 6.3.12 Biomax Informatics AG
  • 6.3.13 Charles River Laboratories
  • 6.3.14 Horiba Ltd.
  • 6.3.15 CD BioSciences
  • 6.3.16 Agile Molecule
  • 6.3.17 BioSolveIT GmbH
  • 6.3.18 Simulations Plus
  • 6.3.19 Genedata AG
  • 6.3.20 Q-Chem Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment